# EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05467748/  
OnCo record `nct05467748` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of tulmimetostat with PD-1 blockade in advanced non-small-cell lung cancer, run by VA Office of Research and Development, now recruiting.

## Summary

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05467748 by VA Office of Research and Development, with VA Greater Los Angeles Healthcare System as collaborator; 66 participants are planned, it started on 2025-12-08; the registry gives 2027-12-08 as its primary completion date. Interventions recorded: Tulmimetostat. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05467748
- Phase: 1/2
- Setting: Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
- Sponsor: VA Office of Research and Development
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT05467748: https://clinicaltrials.gov/study/NCT05467748

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Tulmimetostat](https://onco.cc/drugs/tulmimetostat/)

---
JSON: https://onco.cc/api/v1/entities/nct05467748.json